Paper31064751
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.
Schischlik F and 23 others. Blood, 2019. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Papers, record 31064751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31064751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Myeloproliferative Disorders | Major topic |
| Aged | |
| Calreticulin | |
| Female | |
| Humans | |
| Immunotherapy | |
| Male | |
| Middle Aged | |
| Mutation | |
| Receptors, Thrombopoietin | |
| Sequence Analysis, RNA | |
| Transcriptome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P 29018 | Austrian Science Fund FWF | Austria | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 31296544 | Finding Neo (antigens, that is). | https://conductscience.org/library/papers/31296544 |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29279605 | Cancer transcriptome profiling at the juncture of clinical translation. | Nat Rev Genet | 2018 | https://conductscience.org/library/papers/29279605 | PubMed |
| 2 | 27622333 | Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. | Cancer Cell | 2016 | https://conductscience.org/library/papers/27622333 | PubMed |
| 3 | 23259685 | HLA typing from RNA-Seq sequence reads. | Genome Med | 2012 | https://conductscience.org/library/papers/23259685 | PubMed |
| 4 | 22588898 | Chimeras taking shape: potential functions of proteins encoded by chimeric RNA transcripts. | Genome Res | 2012 | https://conductscience.org/library/papers/22588898 | PubMed |
| 5 | 11687624 | Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11687624 | PubMed |
| 6 | 29132146 | Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. | Nature | 2017 | https://conductscience.org/library/papers/29132146 | PubMed |
| 7 | 28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. | Nature | 2017 | https://conductscience.org/library/papers/28678784 | PubMed |
| 8 | 26565915 | Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. | Cell Rep | 2015 | https://conductscience.org/library/papers/26565915 | PubMed |
| 9 | 26928227 | Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. | Nat Genet | 2016 | https://conductscience.org/library/papers/26928227 | PubMed |
| 10 | 27560107 | The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. | Leukemia | 2016 | https://conductscience.org/library/papers/27560107 | PubMed |
| 11 | 20952405 | COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. | Nucleic Acids Res | 2011 | https://conductscience.org/library/papers/20952405 | PubMed |
| 12 | 27282250 | RNA splicing factors as oncoproteins and tumour suppressors. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/27282250 | PubMed |
| 13 | 25183062 | Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. | BMC Syst Biol | 2014 | https://conductscience.org/library/papers/25183062 | PubMed |
| 14 | 26842708 | Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. | Nat Commun | 2016 | https://conductscience.org/library/papers/26842708 | PubMed |
| 15 | 17406393 | Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. | Nat Protoc | 2006 | https://conductscience.org/library/papers/17406393 | PubMed |
| 16 | 28678778 | An immunogenic personal neoantigen vaccine for patients with melanoma. | Nature | 2017 | https://conductscience.org/library/papers/28678778 | PubMed |
| 17 | 20644199 | The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. | Genome Res | 2010 | https://conductscience.org/library/papers/20644199 | PubMed |
| 18 | 21995386 | Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21995386 | PubMed |
| 19 | 16247014 | The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16247014 | PubMed |
| 20 | 30078747 | Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30078747 | PubMed |
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42860554 | Haematopoietic Cells Deficient for Calreticulin or Expressing Its Oncogenic Variants Maintain Functional Antigen Presentation. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42860554 | PubMed |
| 42806564 | The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy. | Cancer Med | 2026 | https://conductscience.org/library/papers/42806564 | PubMed |
| 41959062 | Platelets Outperform Leukocytes in Transcriptomic Liquid Biopsy Profiling of Myeloproliferative Neoplasms. | bioRxiv | 2026 | https://conductscience.org/library/papers/41959062 | PubMed |
| 41798678 | Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/41798678 | PubMed |
| 41481381 | A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis. | Blood | 2026 | https://conductscience.org/library/papers/41481381 | PubMed |
| 41316436 | Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy. | Biomark Res | 2025 | https://conductscience.org/library/papers/41316436 | PubMed |
| 41011502 | Genomic and Transcriptomic Profiling of a Highly Virulent Plesiomonas shigelloides Strain: Insights into Pathogenicity and Host Immune Response. | Microorganisms | 2025 | https://conductscience.org/library/papers/41011502 | PubMed |
| 40373279 | Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24. | Blood | 2025 | https://conductscience.org/library/papers/40373279 | PubMed |
| 40264064 | Potential application of the bulk RNA sequencing in routine MPN clinics. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40264064 | PubMed |
| 39682299 | Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39682299 | PubMed |
| 39351227 | Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms. | Front Immunol | 2024 | https://conductscience.org/library/papers/39351227 | PubMed |
| 38760666 | Biological relevance of alternative splicing in hematologic malignancies. | Mol Med | 2024 | https://conductscience.org/library/papers/38760666 | PubMed |
| 38731892 | Tumor Antigens beyond the Human Exome. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38731892 | PubMed |
| 38652240 | Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis. | Ann Hematol | 2024 | https://conductscience.org/library/papers/38652240 | PubMed |
| 37915324 | Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations? | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37915324 | PubMed |
| 37666991 | Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. | Nat Genet | 2023 | https://conductscience.org/library/papers/37666991 | PubMed |
| 37662956 | Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow. | Front Immunol | 2023 | https://conductscience.org/library/papers/37662956 | PubMed |
| 37284191 | Mutations, inflammation and phenotype of myeloproliferative neoplasms. | Front Oncol | 2023 | https://conductscience.org/library/papers/37284191 | PubMed |
| 36831689 | Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them? | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831689 | PubMed |
| 36814396 | Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms. | Am J Hematol | 2023 | https://conductscience.org/library/papers/36814396 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CALR | 811 | PubTator's text mining | https://conductscience.org/library/genes/811 | NCBI Gene |
| HLA-C | 3107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| MPL | 4352 | PubTator's text mining | https://conductscience.org/library/genes/4352 | NCBI Gene |
| SF3B1 | 23451 | PubTator's text mining | https://conductscience.org/library/genes/23451 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31064751
GET https://conductscience.org/api/papers/v1/31064751/authors?page=2